Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Measuring cognitive impairment in early Alzheimer’s disease

Dr Suzanne Hendrix, PhD, from Pentara Corporation, Salt Lake City, UT, talks about different techniques for quantifying cognitive impairment and disease progression. She mentions the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) as an effective scale for mild to moderate stages of disease progression, but that earlier stages can benefit from more specific neuropsychiatric evaluations. When comparing the results of different tests, converting values to ‘time-saved’ enables direct comparison, with certain tests performing better at different points of cognitive decline. Recorded at the Alzheimer’s Association International Conference (AAIC)® 2023 held in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Suzanne Hendrix is owner and CEO of Pentara Corporation, a company which consults with dozens of companies in the Alzheimer’s space, including Eisai, Biogen, Lilly, and Nutricia.